Exchanges filled with high-deductible plans

 

As federal and state insurance exchanges enter their second year, from 60 percent to more than 80 percent of plans could be high deductible, reports Modern Healthcare.

“I thought [high-deductible plans] would level off this year and they continue to grow,” said Brigitte Nettesheim, a principal at the Chartis Group, according to the article. “They will still be a significant portion of the type of plan designs offered.”

Read more below:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.